ReviewHeliyon2024
Drug-loaded erythrocytes: Modern approaches for advanced drug delivery for clinical use.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Drug-Loaded Red Blood Cell-Derived Carriers for Targeted Delivery to Accelerate Tissue Regeneration.Pharmaceutics · 2026Article
- Current Advances in Liver-Targeted Drug Delivery: Synthetic, Biological, and Biomimetic Platforms.International journal of molecular sciences · 2026Review
- Pharmacokinetics of Ceftriaxone Encapsulated in Carrier Erythrocytes in Experimental Study.Pharmaceutics · 2026Article
- Biomimetic Targeted Drug Delivery for Liver Failure in Abdominal Sepsis: Focus on Autologous Erythrocyte Ghosts.International journal of molecular sciences · 2026Review
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineering biopolymer nanoparticles for targeted nanomedicine in cancer therapy and food preservation.Frontiers in nutrition · 2026Review
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- Seeing What Sticks: Anchoring Capabilities of Moieties for Use in Cell-Conveyed Therapeutics.Bioconjugate chemistry · 2025Article
- Correlation between spectroscopic and stoichiometric protein to lipid ratios in erythrocyte-derived extracellular vesicles and nanoerythrosomes.Scientific reports · 2025Article
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.International journal of molecular sciences · 2025Review
- Use of encapsulated dexamethasone sodium phosphate (eDSP) in chronic obstructive pulmonary disease, cystic fibrosis, and inflammatory bowel disorders.Frontiers in drug delivery · 2025Review
- Sodium-Selective Channelrhodopsins.Cells · 2024Review
- Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scientific organizations worldwide are striving to create drug delivery systems that provide a high local concentration of a drug in pathological tissue without side effects on healthy organs in the body. Important physiological properties of red blood cells (RBCs), such as frequent renewal ability, good oxygen carrying ability, unique shape and membrane flexibility, allow them to be used as natural carriers of drugs in the body. Erythrocyte carriers derived from autologous blood are even more promising drug delivery systems due to their immunogenic compatibility, safety, natural uniqueness, simple preparation, biodegradability and convenience of use in clinical practice. This review is focused on the achievements in the clinical application of targeted drug delivery systems based on osmotic methods of loading RBCs, with an emphasis on advancements in their industrial production. This article describes the basic methods used for encapsulating drugs into erythrocytes, key strategic approaches to the clinical use of drug-loaded erythrocytes obtained by hypotonic hemolysis. Moreover, clinical trials of erythrocyte carriers for the targeted delivery are discussed. This article explores the recent advancements and engineering approaches employed in the encapsulation of erythrocytes through hypotonic hemolysis methods, as well as the most promising inventions in this field. There is currently a shortage of reviews focused on the automation of drug loading into RBCs; therefore, our work fills this gap. Finally, further prospects for the development of engineering and technological solutions for the automatic production of drug-loaded RBCs were studied. Automated devices have the potential to provide the widespread production of RBC-encapsulated therapeutic drugs and optimize the process of targeted drug delivery in the body. Furthermore, they can expedite the widespread introduction of this innovative treatment method into clinical practice, thereby significantly expanding the effectiveness of treatment in both surgery and all areas of medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.